Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Where COPD came from as a diagnosis

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

COPD is a recent name for an old disease, assembled from two conditions described separately in the 1800s and argued over for most of the twentieth century.

The argument was not pedantic. What people believed the disease was determined what they measured, and the study that settled the practical question produced the single most reproduced graph in respiratory medicine.

Related pages: COPD (chronic lung disease)

The bottom line

What we know
  • Laennec described emphysema in 1819; chronic bronchitis was described separately.
  • The 1959 CIBA guest symposium produced the definitions still broadly used.
  • The term COPD came into wide use in the 1960s.
  • Fletcher and Peto's 1977 study showed that stopping smoking changes the rate of decline.
  • The British and Dutch hypotheses framed decades of research.
What is still open
  • How much the asthma-COPD distinction reflects biology rather than convention.
  • Whether the single label obscures distinct diseases.

The story, step by step

  1. 1. Two diseases ()
  2. 2. The argument ()
  3. 3. The settlement ()
  4. 4. The curve ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 4

Described separately

Small or early study

What happens

The nineteenth century.

What the research shows

  • Rene Laennec, who invented the stethoscope, described emphysema in his 1819 treatise, having examined lungs that remained overinflated after the chest was opened.
  • Chronic bronchitis was described around the same period, associated with the smoke and coal dust of industrialising cities, and was sometimes called the English disease because of its prevalence there.
  • The two were understood as separate conditions, one structural and one inflammatory, for well over a century.
  • Spirometry's ancestor, the spirometer, was developed by John Hutchinson in the 1840s, who measured vital capacity in thousands of people and showed it predicted survival.
  • His instrument was largely used for life insurance assessment rather than clinical diagnosis for many decades.
  • The connection between smoking and lung disease was not established until the mid-twentieth century.

Why it matters

The measurement that defines COPD today existed a century before the disease was named, and was used mainly to price insurance.

What's still uncertain

  • Why Hutchinson's work took so long to enter clinical practice.

Read more

Next: The argument

Part 2 of 4

What to call it

Small or early study

What happens

Britain, the Netherlands and the United States.

What the research shows

  • By the 1950s it was clear that many patients had features of both emphysema and chronic bronchitis, plus airflow obstruction, and that the labels did not match the patients.
  • British clinicians emphasised chronic bronchitis, defining it by cough and sputum, and proposed that mucus hypersecretion and infection drove the decline in lung function. This became the British hypothesis.
  • Dutch researchers proposed instead that asthma, COPD and allergy were expressions of one underlying susceptibility modified by environment, the Dutch hypothesis.
  • American clinicians emphasised emphysema, defined structurally.
  • Each group was describing the same patients with different vocabulary, which made studies difficult to compare across countries.
  • The debate was substantive: if mucus drove decline, treatment should target infection and sputum, and if susceptibility drove it, treatment should target inflammation.

Why it matters

A disagreement about naming turned out to be a disagreement about mechanism, and it shaped what was researched for thirty years.

What's still uncertain

  • How much of the Dutch hypothesis has been vindicated.

Read more

Next: The settlement

Part 3 of 4

CIBA, 1959

Small or early study

What happens

Definitions that still stand.

What the research shows

  • A guest symposium convened at the CIBA Foundation in London in 1959 produced agreed definitions.
  • Chronic bronchitis was defined clinically, by cough and sputum on most days for three months of the year in two consecutive years, a definition still used.
  • Emphysema was defined anatomically, by permanent enlargement of airspaces beyond the terminal bronchioles with destruction of their walls.
  • The symposium also established the importance of measuring airflow obstruction rather than relying on symptoms alone.
  • The umbrella term chronic obstructive pulmonary disease came into wide use through the 1960s, acknowledging that most patients had both components.
  • A parallel American meeting in 1962 produced broadly compatible definitions.

Why it matters

The definitions produced in a London conference room in 1959 remain in textbooks today, which is unusual longevity for clinical nomenclature.

What's still uncertain

  • Whether these definitions remain fit for current practice.

Read more

Next: The curve

Part 4 of 4

Fletcher and Peto, 1977

Small or early study

What happens

The graph that changed advice.

What the research shows

  • Charles Fletcher and Richard Peto followed around 800 working men in west London for eight years, measuring lung function repeatedly.
  • They showed that lung function declines gradually in everyone with age, and faster in susceptible smokers.
  • Critically, they showed that stopping smoking did not restore lost function, but returned the rate of decline toward normal.
  • The resulting graph, usually called the Fletcher-Peto curve, is among the most reproduced figures in respiratory medicine.
  • It also showed that only a susceptible subset of smokers developed severe obstruction, raising the question of why, which is still unanswered.
  • The study largely disproved the British hypothesis that mucus hypersecretion drives the decline, and reframed COPD around progressive airflow obstruction.

Why it matters

The practical message of that curve, that quitting changes the slope rather than the starting point, is still the central message given to patients today.

What's still uncertain

  • Why only a subset of smokers is susceptible.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.